189 related articles for article (PubMed ID: 26757870)
1. [Sézary syndrome treated with extracorporeal photopheresis: Report of one case].
Molgó M; Jaque A; Vial V; Ocqueteau M; Pereira J; Chang M; González S
Rev Med Chil; 2015 Nov; 143(11):1449-58. PubMed ID: 26757870
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
4. Sézary syndrome without erythroderma.
Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
[TBL] [Abstract][Full Text] [Related]
5. Sustained remission of Sézary syndrome.
Bouwhuis SA; McEvoy MT; Davis MD
Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
[TBL] [Abstract][Full Text] [Related]
6. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
7. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
[TBL] [Abstract][Full Text] [Related]
8. Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome.
Bouwhuis SA; el-Azhary RA; Gibson LE; McEvoy MT; Pittelkow MR
J Am Acad Dermatol; 2002 Jul; 47(1):63-7. PubMed ID: 12077583
[TBL] [Abstract][Full Text] [Related]
9. Forced extracorporeal photopheresis (forced-ECP) in Sézary syndrome.
Kreuter A; Gambichler T; Hoffmann A; von Kobyletzki G; Altmeyer P; Hoffmann K
Int J Dermatol; 2001 Jul; 40(7):476-8. PubMed ID: 11679011
[No Abstract] [Full Text] [Related]
10. Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome.
Polansky M; Talpur R; Daulat S; Hosing C; Dabaja B; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):e83-93. PubMed ID: 25458083
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.
Baquero Rey JA; Zambrano Franco EA; Andrade Miranda A; Marciano S; Mazzuoccolo LD; Enz PA
J Clin Apher; 2021 Dec; 36(6):815-822. PubMed ID: 34478581
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.
Booken N; Weiss C; Utikal J; Felcht M; Goerdt S; Klemke CD
J Dtsch Dermatol Ges; 2010 Jun; 8(6):428-38. PubMed ID: 20180887
[TBL] [Abstract][Full Text] [Related]
13. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
14. Retinal toxic reactions following photopheresis.
Vagace JM; Gervasini G; Morais F; Benitez J; Alonso N; de Argila D; Arranz I; Bajo R
Arch Dermatol; 2007 May; 143(5):622-5. PubMed ID: 17515512
[TBL] [Abstract][Full Text] [Related]
15. Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis.
Behle V; von Braunmühl T; Sayehli C; Gesierich A; Goebeler M; Geissinger E; Wobser M
Acta Derm Venereol; 2017 Aug; 97(8):973-975. PubMed ID: 28512672
[No Abstract] [Full Text] [Related]
16. The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas.
Atta M; Papanicolaou N; Tsirigotis P
Transfus Apher Sci; 2012 Apr; 46(2):195-202. PubMed ID: 22067605
[TBL] [Abstract][Full Text] [Related]
17. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome.
Gao C; McCormack C; van der Weyden C; Goh MS; Campbell BA; Twigger R; Buelens O; Harrison SJ; Khoo C; Lade S; Prince HM
Blood; 2019 Oct; 134(16):1346-1350. PubMed ID: 31467061
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides.
Lewis DJ; Duvic M
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28338261
[TBL] [Abstract][Full Text] [Related]
19. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience.
Atzmony L; Amitay-Laish I; Gurion R; Shahal-Zimra Y; Hodak E
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2382-9. PubMed ID: 26299651
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
